The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for Pneumoconiosis.
Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into mature cells typical of several tissues, which have been confirmed in in vivo and in vitro experiments. To investigate the effects of hUC-MSC treatment for Pneumoconiosis, 10 patients with Pneumoconiosis will be enrolled and receive 4 times of hUC-MSC transplantation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.
The second Affiliated Hospital of University of Soth China
Hengyang, Hunan, China
Severity of adverse events
According to National Cancer Institute Common Terminology Criteria for Adverse Events（NCI-CTCAE)
Time frame: 12 months
Immunological Indicator in serum
Expression levels of various cytokines including interferon-γ、IL-2、IL-1β、IL-4 and transforming growth factor-β1 in serum(U/ml).
Time frame: 1, 3 ,6 and 12 months
The level of ceruloplasmin in serum
Time frame: 1, 3 ,6 and 12 months
The level of type Ⅲ procollagen peptide in serum
Time frame: 1, 3 ,6 and 12 months
Lung function as assessed by spirometry
Time frame: 1, 3 ,6 and 12 months
Chest high kilovolt X-ray examination
Time frame: 12 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.